138730-80-0

Usage

1H-Indole-2-carboxylic acid, 5-[[(1,1-dimethylethoxy)carbonyl]amino]-, ethyl ester

The chemical name of the compound, also known as Vilazodone.

Potential antidepressant and anxiolytic properties

The compound has the potential to alleviate symptoms of depression and anxiety.

Selective serotonin reuptake inhibitor (SSRI)

Vilazodone selectively inhibits the reuptake of serotonin, a neurotransmitter involved in mood regulation.

Partial agonist of the serotonin 5-HT1A receptor

Vilazodone also acts as a partial agonist of the 5-HT1A receptor, which is involved in mood and anxiety regulation.

Treatment of major depressive disorder and generalized anxiety disorder

Vilazodone is used to treat these mental health conditions.

Increase levels of serotonin in the brain

By inhibiting the reuptake of serotonin and acting as a partial agonist of the 5-HT1A receptor, Vilazodone increases the levels of serotonin in the brain, which helps to improve mood and reduce anxiety.

Ethyl ester form

The compound is in the form of an ethyl ester, which allows for easier absorption and distribution in the body, making it an effective treatment.

Upstream product

• 71086-99-2 ethyl 5-amino-1H-indole-2-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 16732-57-3 5-nitro-indole-2-carboxylic acid ethyl ester 

Downstream Products

• 1093261-06-3 1,1-dimethylethyl (2-{[({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}methyl)amino]carbonyl}-1H-indol-5-yl)carbamate 
• 1093255-69-6 5-amino-N-({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}methyl)-1H-indole-2-carboxamide trifluoroacetate 
• 1190959-60-4 1,1-dimethylethyl {3-[(2-{[({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}methyl)amino]carbonyl}-1H-indol-5-yl)amino]-3-oxopropyl}carbamate 
• 1093255-74-3 5-(β-alanylamino)-N-({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}methyl)-1H-indole-2-carboxamide 
• 1093255-87-8 N-({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}methyl)-5-(dimethylamino)-1H-indole-2-carboxamide 
• 1093255-88-9 5-[bis(cyclopropylmethyl)amino]-N-({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}methyl)-1H-indole-2-carboxamide 
• 1037795-58-6 C₃₄H₃₂BrN₃O₄ 
• 199806-27-4 5-({5-[4-((2R,3R,4S,5S,6S)-3,4,5-Triacetoxy-6-methoxycarbonyl-tetrahydro-pyran-2-yloxy)-butyrylamino]-1H-indole-2-carbonyl}-amino)-1H-indole-2-carboxylic acid benzyl ester 
• 199806-23-0 benzyl 5-(tert-butyloxycarbonylamino)-2-carboxylate 
• 199806-24-1 5-amino-1H-indole-2-carboxylic acid benzyl ester 
• 138730-81-1 5-[(tert-Butyloxycarbonyl)amino]indole-2-carboxylic Acid 

Relevant academic research and scientific papers

Synthesis and preliminary cytotoxicity study of glucuronide derivatives of CC-1065 analogues

Glucuronide derivatives of CBI-bearing CC-1065 analogues have been synthesized, and their cytotoxicities tested against U937 leukemia cells. The new compounds show potent antitumor activity in vitro. Compounds 1 and 2, and their corresponding glucuronides

CONDENSED 5-OXAZOLIDINONE DERIVATIVE

Provided are condensed 5-oxazolidinone derivatives and pharmaceutically permissible salts thereof, which have excellent anticoagulant effects, are well absorbed orally, and are useful as therapeutic drugs for thrombosis, etc. Compounds represented by form

1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE

A compound represented by formula (1) (in the formula: ring-D represents a three- to eight-membered hydrocarbon ring; Ra represents an optionally substituted amino C1-6 alkyl group or the like; Rb1 and Rb2 each independently represent a hydrogen atom, a halogen atom, or the like; Rc represents an optionally substituted C6-10 aryl group or the like; Rd represents a hydrogen atom or the like; and ring-Q represents a (hetero)aryl group or the like which may be substituted with a carboxyl group or the like) or a pharmaceutically acceptable salt thereof exhibits an excellent FXIa inhibitory activity, and is useful as a therapeutic agent against thrombosis or the like.

CHEMICAL LINKERS AND CLEAVABLE SUBSTRATES AND CONJUGATES THEREOF

The present disclosure provides drug-ligand conjugates and drug-cleavable substrate conjugates that are potent cytotoxins. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.

CHEMICAL LINKERS WITH SINGLE AMINO ACIDS AND CONJUGATES THEREOF

The present disclosure provides drug-ligand conjugates that are potent cytotoxins and include a linker between the drug and ligand where the linker has a single amino acid. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.

CHEMICAL COMPOUNDS

The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.